JP7844468B2 - P2x3阻害剤としてのアミノキナゾリン誘導体 - Google Patents

P2x3阻害剤としてのアミノキナゾリン誘導体

Info

Publication number
JP7844468B2
JP7844468B2 JP2023532331A JP2023532331A JP7844468B2 JP 7844468 B2 JP7844468 B2 JP 7844468B2 JP 2023532331 A JP2023532331 A JP 2023532331A JP 2023532331 A JP2023532331 A JP 2023532331A JP 7844468 B2 JP7844468 B2 JP 7844468B2
Authority
JP
Japan
Prior art keywords
quinazoline
fluorophenyl
methyl
ethyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023532331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550840A5 (cg-RX-API-DMAC7.html
JP2023550840A (ja
Inventor
フィオレッリ,クラウディオ
ブルーノ,パオロ
ビアジェッティ,マッテオ
ピッツィラーニ,ダニエラ
パーラ,ダニエーレ
ロンキ,パオロ
グアリエント,サーラ
バーカー-グレン,チャールズ
デ プール,エルヴェ ファン
ルイーズ ハースト,キム
Original Assignee
キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ filed Critical キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ
Publication of JP2023550840A publication Critical patent/JP2023550840A/ja
Publication of JP2023550840A5 publication Critical patent/JP2023550840A5/ja
Application granted granted Critical
Publication of JP7844468B2 publication Critical patent/JP7844468B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023532331A 2020-11-27 2021-11-26 P2x3阻害剤としてのアミノキナゾリン誘導体 Active JP7844468B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20210189.5 2020-11-27
EP20210189 2020-11-27
PCT/EP2021/083141 WO2022112490A1 (en) 2020-11-27 2021-11-26 Amino quinazoline derivatives as p2x3 inhibitors

Publications (3)

Publication Number Publication Date
JP2023550840A JP2023550840A (ja) 2023-12-05
JP2023550840A5 JP2023550840A5 (cg-RX-API-DMAC7.html) 2024-11-29
JP7844468B2 true JP7844468B2 (ja) 2026-04-13

Family

ID=73642588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023532331A Active JP7844468B2 (ja) 2020-11-27 2021-11-26 P2x3阻害剤としてのアミノキナゾリン誘導体

Country Status (10)

Country Link
US (1) US20240025880A1 (cg-RX-API-DMAC7.html)
EP (1) EP4251620B1 (cg-RX-API-DMAC7.html)
JP (1) JP7844468B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230113309A (cg-RX-API-DMAC7.html)
CN (1) CN116601149A (cg-RX-API-DMAC7.html)
AU (1) AU2021388923A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196333A1 (cg-RX-API-DMAC7.html)
ES (1) ES3026309T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023005803A (cg-RX-API-DMAC7.html)
WO (1) WO2022112490A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026517300A (ja) 2023-05-22 2026-05-28 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ P2x3阻害剤を調製するための方法および中間体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523562A (ja) 2007-04-02 2010-07-15 レノビス, インコーポレイテッド ピリド−2−イル縮合複素環式化合物ならびにその組成物および使用
JP7641917B2 (ja) 2019-05-31 2025-03-07 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ P2x3阻害剤としてのアミノキナゾリン誘導体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2596706T3 (es) 2006-06-29 2017-01-11 F. Hoffmann-La Roche Ag Arilamidas con sustitución de tetrazol
US8076345B2 (en) 2007-04-17 2011-12-13 Evotec Ag 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof
WO2009110985A2 (en) 2008-02-29 2009-09-11 Renovis, Inc. Amide compounds, compositions and uses thereof
US20110237578A1 (en) 2008-09-18 2011-09-29 Zhi-Liang Wei Amide compounds, compositions and uses thereof
WO2016084922A1 (ja) 2014-11-28 2016-06-02 塩野義製薬株式会社 1,2,4-トリアジン誘導体およびその医薬組成物
WO2016088838A1 (ja) 2014-12-04 2016-06-09 塩野義製薬株式会社 プリン誘導体およびその医薬組成物
CU24411B1 (es) 2014-12-09 2019-05-03 Bayer Ag Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
WO2017011729A1 (en) 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
CA2998742C (en) 2015-09-29 2023-08-29 Anthony P. FORD Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523562A (ja) 2007-04-02 2010-07-15 レノビス, インコーポレイテッド ピリド−2−イル縮合複素環式化合物ならびにその組成物および使用
JP7641917B2 (ja) 2019-05-31 2025-03-07 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ P2x3阻害剤としてのアミノキナゾリン誘導体
JP7644029B2 (ja) 2019-05-31 2025-03-11 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ P2x3阻害剤としてのアミノキナゾリン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters,2016年,26,p.3905-3912,DOI: 10.1016/j.bmcl.2016.07.013

Also Published As

Publication number Publication date
MX2023005803A (es) 2023-05-29
EP4251620B1 (en) 2025-04-16
EP4251620C0 (en) 2025-04-16
US20240025880A1 (en) 2024-01-25
AU2021388923A9 (en) 2024-02-08
WO2022112490A1 (en) 2022-06-02
ES3026309T3 (en) 2025-06-11
CA3196333A1 (en) 2022-06-02
JP2023550840A (ja) 2023-12-05
KR20230113309A (ko) 2023-07-28
CN116601149A (zh) 2023-08-15
AU2021388923A1 (en) 2023-05-25
EP4251620A1 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
KR102921974B1 (ko) P2x3 억제제로서 아미노 퀴나졸린 유도체
JP7797204B2 (ja) P2x3阻害剤としてのピリドピリミジン誘導体
ES3023558T3 (en) Phthalazine derivatives as p2x3 inhibitors
EP4251617B1 (en) (aza)quinoline 4-amines derivatives as p2x3 inhibitors
EP4251620B1 (en) Amino quinazoline derivatives as p2x3 inhibitors
RU2821714C2 (ru) Производные аминохиназолина в качестве p2x3 ингибиторов
RU2833037C2 (ru) Производные пиридопиримидинов в качестве ингибиторов p2x3
HK40089089A (en) Amino quinazoline derivatives as p2x3 inhibitors
HK40091208A (en) Phthalazine derivatives as p2x3 inhibitors
BR122024024448A2 (pt) Derivados de amino quinazolina como inibidores de p2x3, composições e usos
HK40057265B (en) Amino quinazoline derivatives as p2x3 inhibitors
HK40062196B (en) Amino quinazoline derivatives as p2x3 inhibitors
HK40057265A (en) Amino quinazoline derivatives as p2x3 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260401

R150 Certificate of patent or registration of utility model

Ref document number: 7844468

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150